Plain-English translation of NCT04985487 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
This is a safety and effectiveness study for brolucizumab, an eye injection used to treat neovascular age-related macular degeneration (a serious eye condition that causes vision loss). Researchers will track how well the medication works and monitor for any side effects in patients who receive it as part of their standard care over 12 weeks, with optional follow-up at 24 and 36 weeks.
Even after a medication is approved and available to patients, it's important to continue monitoring how it performs in real-world use and to identify any safety concerns that might not have been caught in earlier testing.
You would receive brolucizumab injections as prescribed by your eye doctor, and researchers would collect information about your safety and how well the treatment is working. You'll have visits at 12 weeks, and optionally at 24 and 36 weeks, where your eye doctor will monitor your vision and ask about any side effects or concerns you've experienced.
AI-generated summary from trial data ยท Jun 9, 2026 ยท Not medical advice
South Korea